Context Therapeutics Inc.
CNTX
$1.52
-$0.19-11.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.11M | 7.85M | 7.67M | 7.66M | 7.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.52M | 39.70M | 30.21M | 38.30M | 31.63M |
| Operating Income | -43.52M | -39.70M | -30.21M | -38.30M | -31.63M |
| Income Before Tax | -40.23M | -36.12M | -26.44M | -34.21M | -27.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.23 | -36.12 | -26.44 | -34.21 | -27.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.23M | -36.12M | -26.44M | -34.21M | -27.63M |
| EBIT | -43.52M | -39.70M | -30.21M | -38.30M | -31.63M |
| EBITDA | -43.50M | -39.69M | -30.19M | -38.29M | -31.62M |
| EPS Basic | -0.42 | -0.38 | -0.28 | -0.40 | -0.35 |
| Normalized Basic EPS | -0.26 | -0.24 | -0.18 | -0.25 | -0.22 |
| EPS Diluted | -0.42 | -0.38 | -0.29 | -0.40 | -0.35 |
| Normalized Diluted EPS | -0.26 | -0.24 | -0.18 | -0.25 | -0.22 |
| Average Basic Shares Outstanding | 380.74M | 380.74M | 367.49M | 352.79M | 312.56M |
| Average Diluted Shares Outstanding | 380.74M | 380.74M | 367.49M | 352.79M | 312.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |